Intraoperative Near Infrared Molecular Imaging of Lung Cancer

项目摘要/摘要 非小细胞肺癌(NSCLC)是一种严重危害人类健康的疾病，预后不良。当一个病人 首先被诊断为NSCLC的人通常会接受诊断性支气管镜检查和/或 治疗性手术。这两个过程都有限制其成功的技术挑战，例如 活检不准确，未能定位结节和淋巴结，漏诊隐匿性肿瘤，以及阳性 利润率。因此，这些程序的失败率为40%。此项目将使用 在近红外(NIR)范围内进行光学成像，以产生这些问题的实际解决方案 使这两个常见的程序更安全、更有效，并具有更好的结果。的目标是 该项目旨在验证术中成像在靶向的近红外光谱中的假设 分子示踪剂可以识别肿瘤细胞，以改进用于 非小细胞肺癌患者的治疗。本计划项目的创新之处在于 鸡尾酒染料开发、新的近红外摄像设备和临床翻译。有三个具体的 本项目的目标。第一，开发一套靶向近红外分子成像造影剂 它们对非小细胞肺癌上的一系列不同目标敏感和特异。二、发展融合 将高近红外光谱敏感度成像平台集成到常用的白光成像设备中，因此它们 可在临床过程中使用。第三，将这些创新应用于解决常见的临床 问题，以影响病人的护理。如果成功，将提供分子光学成像解决方案 这项提案将立即适用于数十万肺癌患者 每年。

Project Summary/Abstract Non-small cell lung cancer (NSCLC) is a devastating disease with a poor outcome. When a patient is first diagnosed with NSCLC, the person would typically undergo diagnostic bronchoscopy and/or therapeutic surgery. These two procedures have technical challenges that limit their success such as inaccurate biopsies, failure to locate nodules and lymph nodes, missed occult tumors, and positive margins. As a consequence, there is a 40% failure rate for these procedures. This Project will use optical imaging in the near-infrared (NIR) range to generate practical solutions to these problems and make these two common procedures safer, more efficient, and have improved outcomes. The goal of this Project is to test the hypothesis that intraoperative imaging in the NIR spectrum with targeted molecular tracers can identify tumor cells in order to improve procedures that are utilized for the management of patients with NSCLC. The innovation of this Program Project will be in the matrix of cocktail dye development, new NIR camera devices, and clinical translation. There are three specific goals of this Project. First, to develop a set of targeted near-infrared molecular imaging contrast agents that are sensitive and specific to a range of distinct targets on NSCLC. Second, to develop and integrate highly NIR spectral sensitive imaging platforms into commonly used white light imaging devices so they can be utilized during clinical procedures. And third, to apply these innovations to solve common clinical problems in order to impact patient care. If successful, the molecular optical imaging solution presented in this proposal would be immediately applicable to several hundred thousand lung cancer patients each year.